Extranthis UG

Cytisine - Smoking cessation agent

Posted by Dr. from Extranthis UGResponsive · Investment Opportunities in Startups and Spinoffs · Germany

Summary of the technology

- We provide supply of cGMP cytisine API in bulk, produced in FDA inspected installations in the USA, for use as smoking cessation agent.
- We develop a small molecule (natural product) for treatment of opioids use disorder and for pain management.

Extranthis UG
Extranthis UG

Description of the technology

We, at Coryn Pharmaceuticals LLC (US), we require an investment for manufacturing first batch of 1-10kg of cGMP cytisine API. The investment will be recovered from the sales of the manufactured cytisine API.

Current development status

Finished technologies

Use of Proceeds

- Buying raw material Cytisine extract.

Use of Proceeds

Payment of the manufacturing development costs of the cytisine API in bulk.

Technology Owner

Dr. Thomas Kallimopoulos

CEO at Extranthis UG

Related keywords

  • Biological Sciences
  • Medicine, Human Health
  • Pharmaceutical Products / Drugs
  • Protecting Man and Environment
  • Environment
  • Social and Economics concerns
  • Infectious Diseases
  • Therapeutic
  • smoking
  • cigarrettes

About Extranthis UG

Small and Medium Enterprise from Germany

Elaboration of platform technologies for sustainable production of active pharmaceutical ingredients (API) from biomass and using sustainable ressources, respectful to the environment and clima change.
Development of natural products as drugs against addiction and pain management.

Send your request

By clicking "Send your request" you are signing up and accepting our Terms of Service and Privacy policy

Technology Offers on Innoget are directly posted and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.